| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
Telisotuzumab manufacturers
- Telisotuzumab
-
- $372.00
-
2026-07-31
- CAS:1781223-80-0
- Purity: 95.00%
- Supply Ability: 10g
|
| | Telisotuzumab Basic information |
| Product Name: | Telisotuzumab | | Synonyms: | Telisotuzumab;Research Grade Telisotuzumab(DHC34203);ABT-700|||Mab-224G11;Research Grade Telisotuzumab;Telisotuzumab (anti-HGFR);Immunoglobulin G1, anti-(human hepatocyte growth factor receptor) (human-Mus musculus monoclonal ABT-700 heavy chain), disulfide with human-Mus musculus monoclonal ABT-700 κ-chain, dimer (ACI) | | CAS: | 1781223-80-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Telisotuzumab Structure]() |
| | Telisotuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Telisotuzumab Usage And Synthesis |
| Uses | Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity[1]. | | in vivo | Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) effectively antagonizes constitutively activated c-Met and downstream signaling, thereby inhibiting tumor growth in SCID mice with Hs746T cells[1].
| Animal Model: | SCID mice with Hs746T cells[1] | | Dosage: | 2.5-40 mg/kg | | Administration: | i.p., twice a week, 90 days | | Result: | Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk.
Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg.
|
| | References | [1] Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105. DOI:10.1186/s12885-016-2138-z |
| | Telisotuzumab Preparation Products And Raw materials |
|